Wading Biotechnology Co., Ltd. (1733) Reports Q4 2025 Financials: EPS at NT$1.63
Wading Biotechnology Co., Ltd. (stock code 1733) announced its financial results for the fourth quarter of 2025. The company reported basic earnings per share (EPS) of NT$1.63 for the quarter. Quarterly operating revenue reached NT$1.945 billion, with a net profit after tax of NT$163 million. Wading Biotechnology specializes in the biotechnology and medical industry.
📋 Article Processing Timeline
- 📰 Published: December 1, 2025 at 09:00
- 🔍 Collected: April 7, 2026 at 08:00 (3047h 0m after Published)
- 🤖 AI Analyzed: April 8, 2026 at 00:20 (16h 20m after Collected)
Company Code: 1733
Company Name: Wading Biotechnology Co., Ltd.
Industry: Biotechnology and Medical
Year/Quarter: 2025 Q4
Basic Earnings Per Share: NT$1.63
Operating Revenue: NT$1.945 billion
Net Profit After Tax: NT$163 million
Company Name: Wading Biotechnology Co., Ltd.
Industry: Biotechnology and Medical
Year/Quarter: 2025 Q4
Basic Earnings Per Share: NT$1.63
Operating Revenue: NT$1.945 billion
Net Profit After Tax: NT$163 million
FAQ
What is Wading Biotechnology's stock code?
Wading Biotechnology's stock code is 1733.
What were Wading Biotechnology's basic earnings per share (EPS) for Q4 2025?
The basic EPS for Q4 2025 was NT$1.63.
What was Wading Biotechnology's operating revenue in Q4 2025?
The operating revenue for Q4 2025 was NT$1.945 billion.
What was Wading Biotechnology's net profit after tax in Q4 2025?
The net profit after tax for Q4 2025 was NT$163 million.